CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
August 2019—MDxHealth announced that a second clinical validation study demonstrating the performance of its liquid biopsy test SelectMDx for prostate cancer has been published in the Journal of Urology (Haese A, et al. 2019;202[2]:256–263).
In a clinical study of 1,955 men undergoing initial prostate biopsy, SelectMDx yielded a 95 percent negative predictive value and 93 percent sensitivity for the detection of clinically significant prostate cancer.
Pages: 1 2